Background
Methods
Patients and study design
Whole-body vibration platform
Treatment
1st part
2nd part
3rd part
Assessment
Questionnaires and NCI-CTC scoring
Physical examination
Chair-rising test (CRT)
Quantitative sensory testing (QST)
Statistical analysis
Results
Baseline characteristics
Treatment with WBV | Treatment without WBV | p value | |
---|---|---|---|
N = 66 | N = 65 | ||
Sex, male/female | 29/37 | 34/31 | 0.38 |
Age, years, median (Range) | 59 (28–70) | 62 (24–71) | 0.10 |
Diagnosis, no. (%) | 0.85 | ||
Hematological malignancies | 23 (35) | 21(32) | |
Multiple myeloma | 8 (12) | 11 (17) | |
Lymphomas | 10 (15) | 7 (11) | |
Leukemias | 5 (7.5) | 3 (5) | |
Solid tumors | 43 (65) | 44 (68) | |
Colorectal | 13 (20) | 12 (18.5) | |
Lung | 5 (7.5) | 3 (4.5) | |
Esophageal/gastric | 2 (3) | 10 (15) | |
Breast/ovarian | 13 (20) | 12 (18.5) | |
Other | 7 (10.5) | 4 (6) | |
Disease state (excl. leukemias) | |||
Multiple myeloma (Salmon-Durie) | |||
I | 3 | ||
II | 4 | 1 | |
III | 4 | 7 | |
Lymphoma (Ann-Arbor) | |||
I | 1 | ||
II | 1 | ||
III | 4 | 1 | |
IV | 4 | 6 | |
Solid tumors (WHO) | |||
I | 2 | 4 | |
II | 8 | 10 | |
III | 19 | 10 | |
IV | 14 | 20 | |
Pretreatment, no. (%) | |||
Radiotherapy | 28 (42%) | 18 (28%) | 0.10 |
Chemotherapy | 66 (100%) | 65 (100%) | |
Combination chemotherapya
| 64 (97%) | 63 (97%) | 0.99 |
Platinum-based | 27 (41%) | 35 (54%) | 0.16 |
Taxane-based | 22 (33%) | 17 (26%) | 0.45 |
Vinca alkaloids | 9 (14%) | 8 (12%) | 0.99 |
Bortezomib | 6 (9%) | 7 (11%) | 0.78 |
Time since last chemotherapy | |||
In months, median (range) | 2 (0–98) | 0 (0–51) | 0.07 |
Time since first chemotherapy | |||
In months, median (range) | 19 (4–156) | 9 (2–180) | 0.005 |
Treatment related neuropathy | |||
NCI-CTC | |||
Grade II | 28 (42%) | 35 (54%) | 0.22 |
Grade III | 38 (58%) | 30 (46%) | |
Active treatment to control pain, No. (%) | 15 (23%) | 21 (32) | 0.24 |
Chemotherapy during study No. (%) | 25 (38%) | 34 (51%) | 0.12 |
Treatment phase
Evaluation of the primary endpoint
Evaluation of the secondary endpoints
Total | Treatment with WBV | Treatment without WBV | p value | |
---|---|---|---|---|
C-fibers | ||||
Warm detection threshold (WDT) | ||||
Baseline | n = 119 | n = 55 | n = 64 | |
Test-area °C (range) | 12.3 (1.1 to 18.0) | 12.6 (1.3 to 18.0) | 12.1 (1.1 to 18.0) | 0.49 |
Reference-area °C (range) | 1.2 (0.5 to 22.8) | 1.2 (0.5 to 22.8) | 1.2 (0.5 to 17.6) | 0.45 |
After 15 Interventions | n = 87 | n = 40 | n = 47 | |
Test-area °C (range) | 10.4 (1.3 to 18.0) | 9.5 (1.3 to 18.0) | 11.0 (2.7 to 18.0) | 0.09 |
Reference-area °C (range) | 1.3 (0.5 to 15.8) | 1.3 (0.5 to 8.8) | 1.3 (0.5 to 15.8) | 0.72 |
Difference | n = 87 | n = 40 | n = 47 | |
Test-area Δ °C (range) | −0.7 (−13.1 to 16.9) | −1.1 (−13.1 to 6.2) | −0.1 (−10.0 to 16.9) | 0.03 |
Reference-area Δ °C (range) | 0.0 (−22.2 to 2.2) | 0.0 (−22.2 to 2.2) | 0.0 (−16.5 to 2.0) | 0.35 |
Heat pain threshold (HPT) | ||||
Baseline | n = 129 | n = 55 | n = 64 | |
Test-area °C (range) | 48.6 (34.9 to 50.0) | 48.7 (34.9 to 50.0) | 48.3 (39.2 to 50.0) | 0.39 |
Reference-area °C (range) | 44.7 (33.8 to 50.0) | 44.7 (33.9 to 49.5) | 44.7 (33.8 to 50.0) | 0.36 |
After 15 Interventions | n = 87 | n = 40 | n = 47 | |
Test-area °C (range) | 48.5 (37.4 to 50.0) | 48.1 (37.4 to 50.0) | 48.7 (39.9 to 50.0) | 0.47 |
Reference-area °C (range) | 44.9 (33.8 to 50.0) | 44.8 (33.9 to 50.0) | 45.2 (33.8 to 50.0) | 0.48 |
Difference | n = 85 | n = 38 | n = 47 | |
Test-area Δ °C (range) | 0.0 (−7.2 to 8.94) | −0.04 (−3.93 to 3.57) | 0.0 (−3.34 to 3.60) | 0.54 |
Reference-area Δ °C (range) | 0.0 (−4.4 to 0.6) | 0.0 (−0.12 to 4.23) | 0.0 (−0.51 to 2.12) | 0.92 |
Aδ-fibers | ||||
Cold detection threshold (CDT) | ||||
Baseline | n = 110 | n = 56 | n = 64 | |
Test-area °C (range) | −7.8 (−32.0 to 1.7) | −7.6 (−32.0 to −1.7) | −8.4 (−32.0 to −1.9) | 0.35 |
Reference-area °C (range) | −1.2 (−21.9 to 0.5) | −1.1 (−9.7 to −0.5) | −1.4 (-21.9 to −0.5) | 0.08 |
After 15 Interventions | n = 88 | n = 41 | n = 47 | |
Test-area °C (range) | −6.8 (−32.0 to −1.3) | −6.6 (−32.0 to −1.3) | −6.9 (−32.0 to −1.6) | 0.36 |
Reference-area °C (range) | −1.3 (−21.9 to 0.5) | −1.1 (−6.8 to −0.47) | −1.4 (−21.9 to −0.5) | 0.12 |
Difference | n = 85 | n = 38 | n = 47 | |
Test-area Δ °C (range) | 0.7 (−11.1 to 26.9) | 1.1 (−10.1 to 24.9) | 0.7 (−11.1 to 26.9) | 0.46 |
Reference-area Δ °C (range) | 0.0 (−4.0 to 6.7) | 0.0 −0.3 to 6.7) | 0.0 (4.0 to 3.9) | 0.23 |
Aβ-fibers | ||||
Mechanical detection threshold (MDT) | ||||
Baseline | n = 110 | n = 56 | n = 64 | |
Test-area mN (range) | 13.9 (0.2 to 724) | 12.6 (0.9 to 724) | 16.6 (0.2 to 223) | 0.44 |
Reference-area mN (range) | 0.2 (0.2 to 6.1) | 0.2 (0.2 to 6.1) | 0.2 (0.2 to 4.6) | 0.20 |
After 15 Interventions | n = 88 | n = 41 | n = 47 | |
Test-area mN (range) | 17.8 (0.3 to 724) | 19.7 (0.3 to 724) | 17.2 (1.3 to 724) | 0.73 |
Reference-area mN (range) | 0.2 (0.2 to 11.3) | 0.2 (0.2 to 11.3) | 0.2 (0.2 to 4.6) | 0.26 |
Difference | n = 85 | n = 38 | n = 47 | |
Test-area mN (range) | 0.0 (−174 to 501) | 0.8 (−174 to 207) | −3.4 (−105 to 501) | 0.35 |
Reference-area mN (range) | 0.0 (−0.5 to 4.8) | 0.0 (−0.02 to 4.8) | 0.0 (−0.5 to 0.2) | 0.94 |